Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- Data Integrity Risk Detected for Alexion’s Approval-Pending Bleeding Antidote, Report to Panel Put on Hold
September 24, 2021
- Japan Needs Setups to Execute Booster Shots by Year-End: Minister
September 22, 2021
- GSK/Vir’s COVID-19 Drug Up for MHLW Panel Review on Sept. 27
September 22, 2021
- All 4 Contenders in LDP Leadership Race Vow to Expand COVID-19 Measures
September 21, 2021
- MHLW Panel to Discuss Whether Govt Should Investigate Safety of COVID-19 Vaccines
September 21, 2021
- Japan to Start Discussions in October on Reinstating HPV Vaccine Recommendation
September 21, 2021
- Prevent Avigan Use in Potentially Pregnant COVID-19 Patients: Minister
September 21, 2021
- Chuikyo Raises No Objections to MHLW Proposal on Revision of CEA Analysis Process
September 17, 2021
- Japan to Start Pilot Project for Home Use of Antibody Cocktail: Minister
September 17, 2021
- Daiichi Sankyo Missed Goal on CEA Data Submission, but Delay Deemed Reasonable
September 16, 2021
- DPO Minutes to Be Disclosed 2 Months after Chuikyo General Assembly
September 16, 2021
- Tainted Moderna Jabs Run Afoul of PMD Law: Minister
September 16, 2021
- Kazuhito Ihara to Helm Health Policy Bureau; Vice Minister Tarumi to Stay
September 15, 2021
- Japan Eyes Legal System to Ensure Generic Supplies in New Industry Vision, Key Official Says It’s Difficult with Companies’ Own Efforts Alone
September 15, 2021
- MHLW Unapproved Drug Panel Agrees on High Needs for 7 Additional Indications for Fertility Treatments
September 14, 2021
- 16,680 Doses Ruined in Workplace Inoculations; Bayer, Otsuka Too
September 14, 2021
- COVID-19 Jabs Need 3 Month Interval after Antibody Cocktail Use: MHLW
September 14, 2021
- Panel OKs 37 More COVID-19 Jab Health Damage Claims for Compensation
September 14, 2021
- Japan Unveils New Pharma Industry Vision, 1st Update in 8 Years
September 14, 2021
- SaMD Would Be Evaluated Like Ordinary Medical Devices: PMDA Official
September 13, 2021
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…